152 related articles for article (PubMed ID: 36233089)
1. Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing.
Hattinger CM; Casotti C; Patrizio MP; Luppi S; Fantoni L; Scotlandi K; Ibrahim T; Serra M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233089
[TBL] [Abstract][Full Text] [Related]
2. Single-nucleotide polymorphism profiling by multimodal-targeted next-generation sequencing in methotrexate-resistant and -sensitive human osteosarcoma cell lines.
Casotti C; Hattinger CM; Patrizio MP; Luppi S; Fantoni L; Pasello M; Scotlandi K; Ibrahim T; Serra M
Front Pharmacol; 2023; 14():1294873. PubMed ID: 38074116
[No Abstract] [Full Text] [Related]
3. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.
Zhang H; Ge J; Hong H; Bi L; Sun Z
World J Surg Oncol; 2017 Apr; 15(1):75. PubMed ID: 28388903
[TBL] [Abstract][Full Text] [Related]
5. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
6. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
7. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
Cao ZH; Yin HP; Jiang N; Yu B
Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
[TBL] [Abstract][Full Text] [Related]
8. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
Ji WP; He NB
Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
[TBL] [Abstract][Full Text] [Related]
9. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.
Hao T; Feng W; Zhang J; Sun YJ; Wang G
Asian Pac J Cancer Prev; 2012; 13(8):3821-4. PubMed ID: 23098477
[TBL] [Abstract][Full Text] [Related]
10. ERCC polymorphisms and risk of osteosarcoma: a meta-analysis.
Chen XJ; Tong ZC; Kang X; Wang ZC; Huang GL; Yang TM; Dong L
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6658-6666. PubMed ID: 30402838
[TBL] [Abstract][Full Text] [Related]
11. Influence of ERCC2 gene polymorphisms on the treatment outcome of osteosarcoma.
Liu ZF; Asila AL; Aikenmu K; Zhao J; Meng QC; Fang R
Genet Mol Res; 2015 Oct; 14(4):12967-72. PubMed ID: 26505449
[TBL] [Abstract][Full Text] [Related]
12. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
Hattinger CM; Biason P; Iacoboni E; Gagno S; Fanelli M; Tavanti E; Vella S; Ferrari S; Roli A; Roncato R; Giodini L; Scotlandi K; Picci P; Toffoli G; Serra M
Oncotarget; 2016 Sep; 7(38):61970-61987. PubMed ID: 27566557
[TBL] [Abstract][Full Text] [Related]
13. Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?
Kager L; Diakos C; Bielack S
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1025-8. PubMed ID: 25882838
[TBL] [Abstract][Full Text] [Related]
14. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.
Biason P; Hattinger CM; Innocenti F; Talamini R; Alberghini M; Scotlandi K; Zanusso C; Serra M; Toffoli G
Pharmacogenomics J; 2012 Dec; 12(6):476-83. PubMed ID: 21826087
[TBL] [Abstract][Full Text] [Related]
15. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
Hattinger CM; Patrizio MP; Luppi S; Magagnoli F; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):299-311. PubMed ID: 30822170
[TBL] [Abstract][Full Text] [Related]
16. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
[TBL] [Abstract][Full Text] [Related]
17. Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma.
Wang MJ; Zhu Y; Guo XJ; Tian ZZ
Genet Mol Res; 2015 Sep; 14(3):11652-7. PubMed ID: 26436406
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Hattinger CM; Tavanti E; Fanelli M; Vella S; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):245-257. PubMed ID: 27758143
[TBL] [Abstract][Full Text] [Related]
20. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
Yang LM; Li XH; Bao CF
Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
